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Most common genetic disorders have a complex inheritance and may result from variants in many genes, each
contributing only weak effects to the disease. Pinpointing these disease genes within the myriad of susceptibility
loci identiﬁed in linkage studies is difﬁcult because these loci may contain hundreds of genes. However, in any
disorder, most of the disease genes will be involved in only a few different molecular pathways. If we know something
about the relationships between the genes, we can assess whether some genes (which may reside in different loci)
functionally interact with each other, indicating a joint basis for the disease etiology. There are various repositories
of information on pathway relationships. To consolidate this information, we developed a functional human gene
network that integrates information on genes and the functional relationships between genes, based on data from
the Kyoto Encyclopedia of Genes and Genomes, the Biomolecular Interaction Network Database, Reactome, the
Human Protein Reference Database, the Gene Ontology database, predicted protein-protein interactions, human
yeast two-hybrid interactions, and microarray coexpressions. We applied this network to interrelate positional
candidate genes from different disease loci and then tested 96 heritable disorders for which the Online Mendelian
Inheritance in Man database reported at least three disease genes. Artiﬁcial susceptibility loci, each containing 100
genes, were constructed around each disease gene, and we used the network to rank these genes on the basis of
their functional interactions. By following up the top ﬁve genes per artiﬁcial locus, we were able to detect at least
one known disease gene in 54% of the loci studied, representing a 2.8-fold increase over random selection. This
suggests that our method can signiﬁcantly reduce the cost and effort of pinpointing true disease genes in analyses
of disorders for which numerous loci have been reported but for which most of the genes are unknown.
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The completion of various genome-sequencing projects
and large-scale genomic studies has led to a wealth of
available biological data. It is anticipated that this in-
formation will revolutionize our insight into the molec-
ular basis of most common diseases by making it easier
and quicker to identify genes with variants that predis-
pose to disease (i.e., disease genes). At the moment, we
are faced with many disease susceptibility loci, resulting
from linkage or cytogenetic analyses, that cover exten-
sive genomic regions. Usually, when the genes in these
loci are assessed, positional candidate genes become ap-
parent that can be linked to the phenotype being studied
on the basis of their biological function.
However, the most obvious functional candidate gene
from a disease locus does not always prove to be in-
volved in the disease.e.g.,1–5 Often, genes that would not
have been predicted to be disease causing prove to be
the true disease gene—for example, the BRCA1 gene in
early-onset breast cancer.6 Moreover, although these dis-
ease genes might have been assigned biological func-
tions, it is not always evident how these functions relate
to disease. Finally, genes with unknown functions are
often overlooked, as attention is paid only to well-stud-
ied genes for which functions and interactions have been
identiﬁed or implicated, some of which can be related
to the disease pathogenesis. For example, in Fanconi
anemia, at least 10 disease genes were identiﬁed,7 but
only a few had a known function. However, follow-up
research8–10 revealed that ﬁve of those genes function in
the same protein complex. Another example is limb-
girdle muscular dystrophy, in which many of the disease
genes encode for proteins that are part of the dystrophin
complex.11 This emphasizes the importance of taking an
unbiased approach to assessing positional candidate
genes.
Faced with the absence of complete functional infor-
mation for the majority of genes in susceptibility loci, it
is difﬁcult to prioritize the positional candidate genes
correctly for further sequence or association analysis.
However, high-throughput genomic work has now
yielded relatively unbiased genomewide data sets12–15
that comprise known metabolic, regulatory, functional,
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Figure 1 Basic principles of the prioritization method for positional candidate genes with the use of a functional human gene network.
The method integrates different gene-gene interaction data sources in a Bayesian way (left panel). Subsequently, this gene network is used to
prioritize positional candidate genes, with all genes assigned an initial score of zero. In the example (right panel), three different susceptibility
loci are analyzed, each containing a disease gene (P, Q, or R) and two nondisease genes. In each locus, the three positional candidate genes
increase the scores of nearby genes in the gene network, by use of a kernel function that models the relationship between gene-gene distance
and score effect. Genes within each locus are ranked on the basis of their eventual effect score, corrected for differences in the topology of the
network (see the “Material and Methods” section).
and physical interactions. There is, however, little inte-
gration of these diverse data sets into a coherent view
of possible gene and protein interactions that can be used
to investigate relationships between genes in different
genetic loci. We have tried to address this problem by
developing a functional human gene network that
comprises known interactions derived from the Bio-
molecular Interaction Network Database (BIND),12 the
Human Protein Reference Database (HPRD),13 Reac-
tome,15 and the Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG).14
Since these data sets contain a limited number of
known interactions, we implemented a Bayesian frame-
work to complement these relationships with a large
number of predicted interactions by relying on evidence
for putative gene relationships based on biological pro-
cess and molecular function annotations from the Gene
Ontology database (GO).16 We further incorporated ex-
perimental data—namely, coexpression data derived
from ∼450 microarray hybridizations from the Stanford
Microarray Database (SMD)17 and the NCBI Gene Ex-
pression Omnibus (GEO),18 along with human yeast
two-hybrid (Y2H) interactions19 and interactions based
on orthologous high-throughput protein-protein inter-
actions from lower eukaryotes.20
Our interaction network was then used to test whether
we could rank the best positional candidates in suscep-
tibility loci on the basis of their interactions, assuming
that the causative genes for any one disorder will be
involved in only a few different biological pathways.
This would be apparent in our network as a clustering
of genes from different susceptibility loci, resulting in
shorter gene-gene connections between disease genes
than one would expect by chance (ﬁg. 1). Our method
(called “Prioritizer”) analyzes susceptibility loci and in-
vestigates whether genes from different loci can be linked
to each other directly21 or indirectly.22 When we con-
structed artiﬁcial loci of varying size around suscepti-
bility loci from 96 different genetic disorders (each con-
taining at least three loci) and used Prioritizer in our
most comprehensive gene network to rank the positional
candidate genes for each locus, we were able to signif-
icantly increase the chance of detecting disease genes.
Material and Methods
Functional Gene Network Reconstruction
As a basis for the gene network, we used annotations from
Ensembl,23 version 32.35, resulting in 20,334 known genes
that physically map within the autosomes or chromosome
X or Y. This yielded 206,725,611 potential gene-gene
interactions.
On the basis of this set of genes, a comprehensive “gold
standard” set of validated direct gene-gene relationships (true
positives) was determined using both BIND (September 15,
2005) and HRPD (September 15, 2005) to extract human,
curated protein-protein interactions, the proteins of which
were mapped to Ensembl gene identiﬁers. In addition, all hu-
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man pathways from Reactome (September 15, 2005) and
KEGG (September 15, 2005) were used to derive direct inter-
actions that were of transcriptional, physical, or metabolic
origin, since pathways are usually composed of genes and pro-
teins that interact with each other in various ways. We chose
to allow interactions of physical, metabolic, and regulatory
origin to be included within our network, because, for instance,
mutations in either one of two genes encoding proteins in the
same metabolic pathway or protein complex could lead to the
same disease phenotype.
Because the true-positive gold standard only describes a lim-
ited number of relationships between a limited number of
genes, we also used data from GO, coexpression data derived
from microarray experiments, conserved protein-protein high-
throughput data, and human Y2H interaction data to predict
interactions of the remaining gene pairs. We used a Bayesian
classiﬁer, because these four types of data were of varying
reliability and only contained information about a subset of
the data. The classiﬁer allows for combining dissimilar data
sets, can deal with missing data, and uses conditional prob-
abilities that can be well interpreted and that control for the
varying reliability of the data sets.24–29
Training of Bayesian Classiﬁer on Gold Standard
For the prediction of interactions, we used a Bayesian clas-
siﬁer type that assumed all data sets had been binned. This
operation was performed for each gene pair, and it determined,
for each data set, to which bin the pair belongs. Because the
number of bins per data set was limited, each bin contained
many gene pairs. Subsequently, for each bin, we determined
the likelihood ratio between the proportion of gene pairs
known to interact and the proportion of gene pairs known not
to interact. This measure indicates whether there is an over-
or an underrepresentation of truly interacting gene pairs in the
bin, which speciﬁes the conditional probability estimates of
the Bayesian classiﬁer; thus, training of the classiﬁer is
straightforward.
However, to be able to train the classiﬁer by determining
likelihood ratios of sets of gene pairs, it was crucial that the
gold standard, containing the aforementioned well-deﬁned set
of curated true-positive gene pairs, be complemented with a
set of gene pairs for which there is strong evidence that they,
or the proteins they encode, do not functionally interact (true
negatives). As has been discussed by others,30 the construction
of this true-negative reference set is problematic, because it is
impossible to be certain that two genes (i.e., their protein prod-
ucts) do not interact. However, by assuming that genes en-
coding for proteins localized within different cellular com-
partments are, in general, unrelated, it is possible to make a
list of gene pairs that are unlikely to interact. The GO Cellular
Component annotations were used to yield groups of gene
pairs that have exclusive cellular component annotations. To
overcome a strong selection bias in the classiﬁer toward well-
annotated genes (details provided in appendix A [online only]),
only the 5,105 genes that were part of a true-positive gene
pair at least three times were allowed to form true-negative
gene pairs. We chose combinations of cellular organelles that
were highly underrepresented ( ; ) within2 10x p 2,490 P ! 10
the true-positive set, which resulted in gene pairs for the fol-
lowing combinations: nucleus and extracellular matrix, pro-
tein complex and Golgi apparatus, protein complex and Golgi
stack, non–membrane-bound organelle and Golgi stack,
non–membrane-bound organelle and extracellular space, non–
membrane-bound organelle and Golgi apparatus, extracellular
region and organelle membrane, mitochondrion and extracel-
lular matrix, extracellular space and organelle membrane, ex-
tracellular space and Golgi stack, organelle membrane and
extracellular matrix, extracellular matrix and Golgi stack, ex-
tracellular matrix and ubiquitin ligase complex, and ubiquitin
ligase complex and Golgi stack.
Preprocessing and Binning of Data Sets
To allow for Bayesian integration, the GO data, microarray
coexpression data, and orthologous and human protein-pro-
tein interactions data were preprocessed and binned. Biological
Process and Molecular Function GO annotations were derived
from Ensembl, and two measures of relatedness for each of
the two data sets were determined, resulting in a total of four
different GO measures of relatedness. First, we determined,
for each Biological Process GO term, how many of the genes
had been assigned this term. Then, we determined which Bio-
logical Process GO terms were shared between the two com-
ponents of each gene pair, for all the pairs. This led to the
shared GO term that was annotated in the least number of
genes, and its frequency of occurrence was used as a measure.
GO terms GO:0000004 (biological process unknown) and
GO:0005554 (molecular function unknown) were discarded,
since genes that shared either of these highly unspeciﬁc terms
should not be related to each other on the basis of this infor-
mation. The same procedure was performed to generate the
ﬁrst measure of Molecular Function GO relatedness.
The second measure determined the maximal hierarchical
depth at which a gene pair shared a Biological Process GO
term. This hierarchical depth was deﬁned as the shortest num-
ber of branches necessary to go from one Biological Process
GO term back to the GO root. The same method was used to
generate the maximum hierarchical depth of the Molecular
Function GO sharing measure.
Coexpression between genes was determined in microarray
data sets from GEO and SMD. Individual data sets comprised
an experiment that contained at least 10 hybridizations. To
ensure that the quality of the intensity measurements was re-
liable, various ﬁltering steps were performed to exclude spots
with low signal-to-noise ratios.31 Within the SMD data sets,
intensity spots were ﬁltered out that were either missing or
contaminated, and the mean intensity of spots had to be at
least 2.5 times higher than the average background signal of
the microarray. Since GEO contains both ratiometric and Af-
fymetrix single-spot intensity microarray data sets, we used
different ﬁltering strategies. The 5% of genes with the lowest
maximal intensity were removed from the Affymetrix data sets.
For both SMD and GEO, expression ratios were log2 trans-
formed. Microarray features missing 25% of expression
measurements in a data set after ﬁltering were excluded. All
features were assigned Ensembl gene identiﬁers by compar-
ing their sequences to Ensembl transcripts with the use of
SSAHA.32
To determine which gene pairs showed coexpression, the
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Figure 2 Integration of data sets in four gene networks. a, Data sets were benchmarked against a set of 55,606 known true-positive gene
pairs derived from BIND, KEGG, HPRD, and Reactome and 800,608 true-negative gene pairs derived from GO. The Venn diagram indicates
the data sources from which the true positives were derived and their degree of overlap. Numbers in parentheses indicate the number of
interactions that are provided by each of the data sets. b, Potential gene-gene interactions derived from GO, microarray coexpression data, and
human and orthologous protein-protein interaction data were integrated using a Bayesian classiﬁer. The steps involved in building this classiﬁer
are shown.
mutual information was calculated between all the genes rep-
resented within each data set33 if there were at least 10 non-
missing data points. As a preprocessing step, expression levels
were ranked; this invertible reparameterization did not affect
the mutual information. Next, for each pair of genes, the joint
distribution of expression levels was estimated by calculating
a histogram with overlapping windows. The range was divided
into six windows, where each window extends to the center
of the next window. The number of windows was chosen by
optimizing the error rate for the mutual information derived
from analytical probability densities.33 In this way, each data
point contributes to two windows, except at the extremities.
Finally, on the basis of the resulting distribution, the mutual
information (MI) between each pair of genes was calculated
as , where H(X) is the in-MI(A,B)pH(A)H(B)H(A,B)
formation-theoretic Shannon entropy.34 For each microarray
data set, the MI score was binned. This allowed the subsequent
Bayesian classiﬁer to determine the likelihood ratio, indicating
whether gene pairs within each bin contained an overrepre-
sentation of truly interacting gene pairs. Once the likelihood
ratios had been determined for each data set, a receiver op-
erator characteristic (ROC) curve was constructed, and the
area under the curve (AUC) was calculated. Data sets that had
a minimal AUC of 0.59 were combined in a naive way—for
each gene pair, the likelihood ratios were multiplied by each
other, resulting in a ﬁnal microarray coexpression likelihood
ratio for each gene pair.
Two orthologous protein-protein interaction data sets from
Lehner and Fraser20 were used to supplement the GO and
microarray coexpression data. One data set contained com-
putationally predicted human protein interactions that had
been physically mapped within Ensembl genes. The second
data set contained a subset of these protein pairs, to which
Lehner et al. had assigned a higher conﬁdence. Three bins were
constructed: one containing the higher-conﬁdence gene pairs,
one containing the remaining lower-conﬁdence pairs, and a
third containing all the other unobserved gene pairs.
A human Y2H protein-protein interaction data set from
Stelzl et al.19 was integrated by mapping the HUGO identiﬁers
to Ensembl genes. Two bins were constructed: one containing
the gene pairs for which a Y2H interaction was reported, and
one containing all the other unobserved gene pairs.
Network Integration
The Bayesian classiﬁer was employed to integrate the various
binned types of data. We chose not to learn the Bayesian net-
work structure from the data but to use a predeﬁned Bayesian
network structure, for which the conditional probabilities were
determined by benchmarking the various data sets against the
gold standard (ﬁg. 2) (details provided in appendix A). We
subsequently generated four gene networks. One network con-
tained evidence for interaction based on the GO data (GO
network). Another network contained evidence for interaction
derived from integrating the microarray coexpression and
predicted protein-protein interaction data in a naive way
(MAPPI network). A third network combined, in a naive
way, the GO and MAPPI networks (GOMAPPI net-
work), and this was complemented with all known true-pos-
itive interactions in a ﬁnal network (GOMAPPITP net-
work). To relate interacting genes directly or indirectly, an
all-pairs shortest path was calculated for each gene network.35
This measure of the minimal path length between pairs of genes
was used in the subsequent method to associate disease genes
with each other.
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Disease Analysis and Positional Candidate-Gene
Prioritization
Prioritizer assesses whether genes residing within different
susceptibility loci are close together within the gene network.
This indicates that this method could also work with diseases
for which only two loci have been identiﬁed. However, in such
a case, there is a considerable probability that two genes, each
residing in a different locus, would interact by chance. We
therefore restricted the analysis to diseases for which at least
three contributing disease genes had been identiﬁed. These dis-
eases and disease genes were derived from the Online Men-
delian Inheritance in Man (OMIM) database,36 by text mining
the ﬁrst paragraphs of all OMIM disease entries as of March
1, 2005, and extracting the OMIM gene numbers contained
within these paragraphs (table A1 in appendix A). The HUGO
gene name was later extracted from these OMIM entries and
was mapped to an Ensembl gene name. If, for any one disease,
there were two disease genes situated at the same chromosome
and positionally !200 genes apart, one of the two genes was
randomly removed to ensure that no loci would overlap.
The diseases for which at least three disease genes remained
after ﬁltering were analyzed by artiﬁcially generating suscep-
tibility loci around the disease genes, in a range from 50 to
150 genes, in steps of 50. All 20,334 genes were assigned an
initial effect score of zero, and, subsequently, all loci were
traversed. Using each gene network for all positional candidate
genes residing in a particular locus, we determined whether
any of these genes were functionally closely related to genes
physically residing inside another susceptibility locus. If this
was the case, the effect score of the related gene that was
functionally close but physically in another locus increased (ﬁg.
1), by use of the following Gaussian kernel scoring function:
2distance
53effectp e ,
where “distance” is deﬁned as the all-pairs shortest path be-
tween the two genes. The kernel function width was chosen
arbitrarily, but a sensitivity analysis showed that different
widths did not inﬂuence the results much (data not shown).
By applying this function, positional candidate genes that re-
sided in different loci but that were functionally closely related
in the gene network were assigned higher scores than positional
candidate genes that were functionally far apart from each
other. To correct for differences in topology of the gene net-
work, an empiric P value was determined for each positional
candidate gene through permutation of the other loci 500 times
by reshufﬂing them across the genome and recalculating the
effect scores. This permitted a probability density function to
be determined per positional candidate gene, for which the
empiric P value could be looked up. For each locus, the po-
sitional candidate genes were prioritized on the basis of this
P value.
Results
Construction of a Functional Gene Network
The basis for our human gene network was a gold
standard of validated gene-gene interactions (true pos-
itives) and a further set of gene-gene pairs that were
deemed highly unlikely to interact (true negatives). To
construct the set of true-positive gene pairs, 2,788 con-
ﬁrmed, direct, physical protein-protein interactionswere
derived from BIND; 18,176 conﬁrmed human protein
interactions were derived from HPRD; 22,012 direct
functional interactions were derived from KEGG; and
16,295 interactions were derived from Reactome. This
resulted in 55,606 unique true-positive gene relation-
ships (ﬁg. 2a). For the true-negative set, gene pairs were
selected that encode for proteins localized in different
cellular compartments. The combinations of cellular
compartments were selected from their underrepresen-
tation in the set of true positives (see the “Material and
Methods” section). This resulted in 801,108 pairs, of
which 500 were known to be true-positive gene pairs,
and these were therefore removed from the set of true-
negative gene pairs.
We trained the classiﬁer on this gold standard and
constructed functional human gene networks on the ba-
sis of GO data, microarray coexpression data, and in-
ferred protein-protein interactions, as well as combi-
nations of these. First, for each gene pair, we assessed
whether the genes shared GO annotations, which were
derived for 15,045 genes from Ensembl. Sharing of GO
terms was based on the frequency of the least-common
GO term shared between two genes and the maximal
depth in the GO hierarchy at which two shared terms
lay. Gene coexpression was calculated in 186microarray
data sets derived from GEO and 75 data sets from SMD.
However, most of these data sets were not highly infor-
mative, as judged by their ability to identify true-positive
gene interactions with a low false-positive rate. Because
it is known that many classiﬁers perform best when a
subset of features are used,37,38 we used only four infor-
mative microarray coexpression data sets for classiﬁ-
cation,39–42 each showing a minimal AUC of 0.59. In
total, these data sets contained 461 microarray hybrid-
izations. Finally, protein-protein interactions were de-
rived from the Lehner and Fraser20 data set containing
human protein interactions predicted by mapping phys-
ical protein interactions from various Saccharomyces
cerevisiae, Drosophila melanogaster, and Caenorhab-
ditis elegans interaction data sets to orthologous human
gene pairs. Of the 71,806 predicted gene pairs, we were
able to physically map 62,635 gene pairs with both genes
in the pair mapping to known Ensembl genes. A subset
was deﬁned by Lehner and Fraser20 that contained
10,652 gene pairs deemed to be of higher conﬁdence, of
which 10,139 gene pairs could be mapped. In addition,
we used 3,186 human protein-protein interactions iden-
tiﬁed by automated Y2H interaction mating by Stelzl et
al.,19 of which 1,751 could be mapped to different En-
sembl gene pairs.
We assessed the performance of our classiﬁer on the
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Figure 3 ROC curve of the GO network, the MAPPI network,
and the combined GOMAPPI network. The baseline (solid gray
line) indicates the performance of a classiﬁer that would be totally
uninformative.
basis of these various data sources in three different gene
networks generated on the basis of a Bayesian frame-
work, after preprocessing and binning of the data sets.
As mentioned above, one network was generated solely
on the basis of GO data (GO network), one network
was based on both microarray coexpression and pre-
dicted protein-protein interaction data (MAPPI net-
work), and an overall network contained all three types
of data (GOMAPPI network). ROC curves (ﬁg. 3)
show the performance of the reconstructed GO,MAPPI,
and GOMAPPI gene networks, which were con-
structed by cross-validating all data sets 10 times against
the gold standard set, to mitigate overﬁtting (details pro-
vided in appendix A). When we compared the perfor-
mance of the various gene networks, it became evi-
dent that the GO data set provided the most accurate evi-
dence for interaction. The AUCwas 88%, comparedwith
50% for an uninformative classiﬁer. The ROC for the
MAPPI network shows that coexpression data derived
from microarray expression, in conjunction with the or-
thologous protein-protein interaction data, correctly in-
ferred functional interactions ( ), but to aAUCp 68%
lesser extent than the GO network. Nevertheless, as can
be deduced from the GOMAPPI network, addition
of the microarray coexpression and the orthologous pro-
tein-protein interaction data to the GO network im-
proved slightly the accuracy of the network (AUCp
). In accordance with most networks described in90%
the literature thus far,43 our reconstructed networks have
a connectivity that follows a scale-free power-law dis-
tribution, which has also been demonstrated for other
organisms.44–46 This is most apparent when the topology
of the MAPPI network is assessed (see appendix A).
To validate our network, we used a list of 2,574 Y2H
interactions that recently became available47 to assess
whether our gene network had predicted an interaction
for these gene pairs. We ﬁrst mapped the set to Ensembl
pairs and then removed all pairs that were in our gold
standard true-positive set, to ensure that we only as-
sessed newly identiﬁed interactions. This resulted in a
set of 1,318 novel gene pairs.
We then assessed whether our gene network had pre-
dicted an interaction for these pairs. While Y2H inter-
actions are known to regularly yield false-positive re-
sults,48 we decided to test whether the distribution of
likelihood ratios for these gene pairs was signiﬁcantly
different from a null distribution of 10,000 gene pairs
sampled by generation of random gene pairs by selecting
two genes at a time from the set of all individual genes
that made up the Y2H gene pairs. The results show that
the 1,318 Y2H gene pairs have a signiﬁcantly higher
likelihood ratio than the null distribution ( ,Pp .0003
by Wilcoxon Mann-Whitney test), which indicates that
our gene network is capable of inferring as-yet-unknown
interactions.
To allow researchers to look up known and predicted
interactions and to identify the shortest routes between
genes and susceptibility loci, we developed a Web tool,
which is publicly available at the GeneNetworkWeb site.
The known and predicted interactions can be shown for
each gene of interest, along with information about the
source of evidence from which they were derived and
how strong this evidence was. In addition, there are in-
teractive graphs to visually explore how multiple genes
interact with each other. All the data ﬁles (including the
sets of true-positive and true-negative gene pairs) can be
downloaded, along with a Java application program-
ming interface, which can facilitate the development of
new methods that use this gene network. Every 2 mo,
we will update the gene network, on the basis of the
most recent releases of the various repositories used in
its construction.
Increased Functional Interactions Shown by Genes
Associated with a Particular Disease
We ﬁrst examined our hypothesis that genes associ-
ated with genetic disorders frequently share functional
links, by assessing whether, for a disease, these causative
genes were functionally more closely related to each
other than a set of genes of equal size that were randomly
selected from the full set of 345 unique disease genes of
the 409 disease genes that were extracted from OMIM
entries on disorders for which at least three causative
genes were known. This set of disease genes was used
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as a background distribution to prevent bias, since the
disease genes are generally better characterized than the
complete set of genes in the network. We generated one
extra network (GOMAPPITP network) that com-
plemented the GOMAPPI network with all known
true-positive gene pairs, and we calculated the shortest
direct or indirect distance between all pairs of genes. In
76 (79%) of the 96 diseases, the total distance between
all combinations of disease genes in one disease was, on
average, lower than the total distance between all com-
binations of randomly selected disease genes in 10,000
permutations. This conﬁrms our hypothesis that, in the
majority of diseases, the causative genes are indeed
closely related functionally.
Genes implicated in disease processes tend to be stud-
ied more than those not implicated, which could result
in a bias in the gene network based on GO annotations,
since these represent known functional annotations. To
assess the degree to which this possible bias affected our
gene network, we looked at network connectivity. The
average number of direct interactions involving disease
genes was 199, compared with an average of 203 for
the other 11,875 genes that interacted with at least one
other gene. This indicates that other genes are equally
represented in the gene network, despite the fact that
disease genes may have been studied more.
Increased Power to Detect Disease Genes Provided
by a Functional Gene Network
Usually, researchers pick a limited number of candi-
date genes in susceptibility loci to follow-up, because it
is too costly and labor intensive to analyze all the genes
residing in these loci. As a result, these studies have a
limited chance of ﬁnding disease-related variants, largely
depending on the size of the loci and the number of
genes selected. Using a test set of known disorders in a
similar setup, we evaluated the ability of our recon-
structed network to correctly prioritize positional can-
didate genes in a set of top-ranked candidate genes of
typical size (5–10 genes). The test set consisted of 96
different disorders, for which a total of 409 disease genes
(345 unique genes) had been identiﬁed. These were ob-
tained from OMIM, with 3–10 disease genes per disease
(average 4.3 genes per disease) (table A1 in appendix
A). Of the diseases, 59 are of Mendelian origin, 17 have
complex inheritance, and 20 are various types of cancer
(table 1).
The ability of the functional human gene network to
correctly prioritize known disease genes was assessed by
creating artiﬁcial, nonoverlapping susceptibility loci
around these disease genes. Since many genes in these
loci have no known or predicted interactions in our net-
work, we only assessed those genes for which interac-
tions were predicted, to prevent a bias toward genes that
were better represented in the underlying high-through-
put data sets. This resulted in susceptibility loci of vary-
ing widths, containing 50, 100, or 150 genes, whichwere
predicted to interact with at least one other gene. If, for
any particular disease, two disease genes residing in the
same chromosome yielded loci that were partly over-
lapping, one of the two loci was randomly removed.
For each locus, the genes were traversed, and, for each
gene, we assessed whether there was another gene re-
siding in a different locus that was nearby within the
gene network. The effect scores (see the “Material and
Methods” section) of each gene were affected by the gene
in the other locus that had the shortest path to that gene.
This procedure has the potential to preferentially identify
genes with many interacting partners over genes that are
less well connected, because a highly connected gene has
a higher chance of interacting with a gene residing in
another locus than a gene for which only a few inter-
actions have been predicted. To overcome bias in the
method toward genes that are highly connected, we cor-
rected for differences in the network topology by per-
muting the susceptibility loci for each disease 500 times
across the genome.
After all positional candidate genes were ranked on
the basis of this permuted score, the results (see ﬁg. 4
and table 1) indicated that this method was able to iden-
tify many of the disease genes in the top 5 or top 10
genes per locus. As expected from the ROC curves of
the various gene networks (ﬁg. 3), the performance of
the MAPPI network proved to be the least powerful.
Nevertheless, the number of correctly ranked genes was
higher than would be expected to occur by chance (ﬁg.
4a and 4b; indicated by baseline) for many of the sus-
ceptibility loci widths. When assessing susceptibility loci
that contained, on average, 100 genes, we found 8%
and 12% of the disease genes were contained within the
top 5 and top 10 per locus, respectively, compared with
the 5% and 10% we would expect to ﬁnd by chance.
A lack of predictive performance of the MAPPI net-
work explains why the ranking did not improve consid-
erably when this network was used, as is evident from
inspection of the ROC curves (ﬁg. 4c), which show the
proportion of disease genes and nondisease genes that
are returned when different sizes of sets of top-ranked
genes per locus are assessed. For 86 of the 345 unique
disease genes within the MAPPI network, no inter-
actions were predicted. Hence, they were ranked low,
the more so because the 49, 99, or 149 other genes,
residing together with each disease gene in the con-
structed susceptibility loci, had been selected on the
premise that they interacted with at least one other gene.
The GO network performed considerably better; when
we used it to assess susceptibility loci that contained, on
average, 100 genes, we found 16% and 24% of the dis-
ease genes were contained within the top 5 and top 10
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Table 1
Overview of the 96 Diseases Studied with Prioritizer and the Number of Disease Genes per Disorder That Ranked in the Top 10 Genes per Susceptibility Locus, With Locus
Widths of 100 and 150 Genes
DISEASE TYPE AND DISEASE
OMIM
NUMBER
NO. OF
GENES
NO. OF GENES RANKING IN TOP 10
AT LOCUS WIDTH OF 100 GENES
NO. OF GENES RANKING IN TOP 10
AT LOCUS WIDTH OF 150 GENES
MAPPI GO GOMAPPI GOMAPPITP MAPPI GO GOMAPPI GOMAPPITP
Mendelian inheritance (59 diseases):
Achromatopsia 2 216900 3 0 0 1 0 0 0 0 0
Achromatopsia 3 262300 3 0 0 1 0 0 0 0 0
Adrenoleukodystrophy, autosomal neonatal form 202370 5 0 4 2 4 0 4 2 3
Amyloidosis VI 105150 3 1 1 0 1 0 0 0 1
Amyloidosis, familial visceral 105200 3 0 0 0 0 0 0 0 0
Amyotrophic lateral sclerosis 1 105400 5 0 1 0 0 0 1 0 0
Atypical mycobacteriosis, familial 209950 5 1 4 2 4 1 1 0 1
Autonomic control, congenital failure of 209880 5 0 0 1 1 0 0 1 1
Bardet-Biedl syndrome 209900 8 0 2 2 3 0 1 1 1
Bare lymphocyte syndrome, type II 209920 4 1 0 1 4 0 0 1 4
Cardiomyopathy, familial hypertrophic 192600 9 0 7 4 4 0 7 3 3
Cholestasis, intrahepatic, of pregnancy 147480 3 1 0 0 0 0 0 0 0
Cholestasis, progressive familial intrahepatic 1 211600 4 1 1 1 0 0 1 1 1
Complex I, mitochondrial respiratory chain, deﬁciency of 252010 5 0 5 4 5 0 3 3 3
Coumarin resistance 122700 4 0 0 0 1 0 0 0 0
Dementia, Lewy body 127750 3 1 0 0 0 0 0 0 0
Epidermolysis bullosa junctionalis, disentis type 226650 4 1 0 1 0 0 0 0 0
Epidermolysis bullosa of hands and feet 131800 4 0 1 2 1 0 0 1 1
Fanconi anemia 227650 6 1 0 1 6 1 0 0 6
Fundus albipunctatus 136880 4 0 1 0 3 0 1 1 2
Generalized epilepsy with febrile seizures plus 604233 3 2 2 2 1 1 0 1 0
Glutaricaciduria IIA 231680 3 3 2 3 3 3 1 3 3
Hermansky-Pudlak syndrome 203300 6 0 1 0 0 0 0 0 0
Hirschsprung disease 142623 6 1 0 0 1 1 0 0 1
Hydrops fetalis, idiopathic 236750 4 0 0 1 0 0 0 1 0
Hypercholesterolemia, familial 143890 6 0 2 3 1 0 1 2 1
Hypertrophic neuropathy of Dejerine-Sottas 145900 4 0 2 2 2 1 1 1 1
Hypokalemic periodic paralysis 170400 3 0 0 0 2 0 0 0 0
Ichthyosiform erythroderma, congenital, nonbullous, 1 242100 3 0 2 2 1 0 1 1 1
Immunodeﬁciency with hyper-IgM, type 2 605258 3 0 1 0 2 0 1 0 1
Immunodeﬁciency with hyper-IgM, type 3 606843 3 0 2 0 2 0 1 0 1
Kartagener syndrome 244400 3 1 2 2 1 0 2 2 1
Keratosis palmoplantaris striata I 148700 3 0 1 1 3 0 1 1 3
Laron syndrome, type II 245590 3 0 1 0 2 0 0 0 1
Leber congenital amaurosis, type I 204000 7 0 3 2 1 0 0 1 2
Leigh syndrome 256000 6 3 4 3 3 1 4 3 3
Leukoencephalopathy with vanishing white matter 603896 5 5 5 5 5 5 5 5 4
Maple syrup urine disease, type IA 248600 4 1 1 1 4 0 0 0 3
Maturity-onset diabetes of the young 606391 5 1 0 1 3 1 0 1 0
Myasthenic syndrome, congenital, fast-channel 608930 3 0 2 2 3 0 2 2 3
Myasthenic syndrome, slow-channel congenital 601462 3 0 2 2 1 0 2 2 2
Myoclonic dystonia 159900 3 0 0 0 1 0 0 0 1
Nemaline myopathy 1, autosomal dominant 161800 3 0 1 1 0 0 1 1 0
Nesidioblastosis of pancreas 256450 3 0 1 0 0 0 1 1 0
Night blindness, congenital stationary 163500 3 0 0 1 0 0 0 0 0
1019
Obsessive-compulsive disorder 1 164230 3 0 1 0 0 0 0 0 0
Ossiﬁcation of the posterior longitudinal ligament of spine 602475 3 0 0 0 1 0 0 0 0
Osteopetrosis, autosomal recessive 259700 3 1 0 0 0 0 0 0 0
Peters anomaly 604229 4 0 0 1 2 0 0 0 0
Pituitary dwarﬁsm III 262600 3 0 0 0 2 0 0 0 1
Progressive external ophthalmoplegia 157640 3 1 1 0 0 0 0 0 0
Pseudohypoaldosteronism, type I, autosomal recessive 264350 3 0 2 2 1 0 2 2 0
Pulmonary alveolar proteinosis 265120 3 0 2 1 0 0 2 1 0
Refsum disease, infantile form 266510 3 1 1 1 2 0 1 1 2
Reticulosis, familial histiocytic 267700 3 0 0 0 0 0 0 0 0
Rhizomelic chondrodysplasia punctata, type 3 600121 3 0 1 0 2 0 1 0 1
Stickler syndrome, type I 108300 3 0 0 0 2 0 0 0 0
Waardenburg-Shah syndrome 277580 3 0 1 1 1 0 2 1 0
Zellweger syndrome 214100 8 1 4 4 7 1 3 4 5
Complex inheritance (17 diseases):
Alzheimer disease 104300 8 0 1 0 3 0 1 1 2
Diabetes mellitus, non–insulin-dependent 125853 9 2 0 3 1 1 0 2 2
Elliptocytosis, Rhesus-unlinked type 130600 3 0 1 0 3 0 1 0 2
Graves disease 275000 3 0 1 0 1 0 0 0 0
Hypertension, essential 145500 7 1 1 0 0 0 0 0 0
Hypospadias 146450 3 0 0 0 1 0 0 0 1
IgA nephropathy 161950 4 1 0 0 1 1 0 0 1
Inﬂammatory bowel disease 1 266600 4 0 0 1 1 0 0 0 1
Longevity 152430 4 0 1 0 0 1 0 0 0
Lupus erythematosus, systemic 152700 4 0 0 0 0 0 0 0 0
Mycobacterium tuberculosis, susceptibility to infection by 607948 3 0 0 0 0 0 0 0 0
Myoclonic epilepsy, juvenile 606904 4 0 1 0 1 0 1 0 0
Obesity 601665 7 1 1 1 4 2 0 1 3
Osteoporosis, involutional 166710 5 0 1 1 0 0 3 1 2
Parkinson disease 168600 4 0 0 0 4 0 1 0 3
Rheumatoid arthritis 180300 5 0 0 0 0 0 0 0 1
Sudden infant death syndrome 272120 3 0 2 2 0 0 1 1 0
Heritable cancer (20 diseases):
Bladder cancer 109800 3 0 0 0 0 0 0 1 0
Breast cancer 114480 10 2 1 4 2 1 0 2 1
Chondrosarcoma 215300 4 1 1 0 2 0 0 0 1
Esophageal cancer 133239 8 1 0 1 5 1 0 0 2
Glioma of brain, familial 137800 6 1 1 1 0 2 1 0 0
Hepatocellular carcinoma 114550 3 0 0 0 1 1 0 0 0
Juvenile myelomonocytic leukemia 607785 4 0 3 2 1 0 1 1 1
Leiomyoma, uterine 150699 4 0 0 1 0 0 0 0 0
Lung cancer 211980 4 1 0 1 2 0 0 1 0
Lymphoma, non-Hodgkin, familial 605027 4 0 2 2 2 0 1 1 2
Medulloblastoma 155255 4 1 0 2 2 1 0 1 0
Myeloma, multiple 254500 4 1 1 0 0 1 0 0 1
Osteogenic sarcoma 259500 3 0 0 0 0 0 0 0 1
Pancreatic carcinoma 260350 6 1 1 1 0 1 0 1 0
Pheochromocytoma 171300 3 0 0 0 0 0 0 0 0
Prostate cancer 176807 9 1 0 1 0 0 0 0 0
Renal cell carcinoma, papillary 605074 3 1 0 0 1 1 0 0 1
Rhabdomyosarcoma 2 268220 3 0 0 0 0 0 0 0 0
Thyroid carcinoma, papillary 188550 5 2 0 0 0 1 0 0 0
Turcot syndrome 276300 3 2 2 2 1 2 2 3 2
Total 409 49 (12%) 99 (24%) 93 (23%) 138 (34%) 33 (8%) 67 (16%) 68 (17%) 98 (24%)
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Figure 4 Accuracy of positional candidate-gene prioritization. a and b, Percentage of the 409 disease genes that was ranked among the
top 5 (a) or top 10 (b) genes per locus, after artiﬁcial susceptibility loci of varying widths around these genes were constructed and when
different types of gene networks were used. The baselines (gray lines) indicate the percentage of disease genes expected to rank among the top
5 or top 10 genes by chance. c, ROC curves for susceptibility loci that contain 50, 100, or 150 genes.
genes per locus, respectively. The performance of the dis-
ease analysis was best when the inferred GOMAPPI
network was complemented with the known true-pos-
itive interactions (GOMAPPITP network); with
this network and an average susceptibility locus width of
100 genes, 27% and 34% of the disease genes were con-
tained within the top 5 and top 10 per locus, respectively.
We also assessed the probability of detecting at least
one disease gene when only a ﬁxed number of top-
ranked genes per locus is followed up (ﬁg. 5). When we
employed the most comprehensive GOMAPPITP
network and followed up all the top 5 or top 10 posi-
tional candidate genes for each disorder, using locus
widths of 100 and 150 genes, we found at least one
disease gene from these top sets of genes in 54% and
64% of the diseases, respectively, compared with 19%
and 35% expected by chance. When we conﬁned our
analysis to diseases for which at least four or ﬁve disease
genes were known, the performance of our method in-
creased slightly (data not shown), because the true dis-
ease genes now interacted with more of the other true
disease genes, increasing their overall scores.
Breast Cancer as an Example
We selected breast cancer as an example of how the
various gene networks perform in a complex disease for
which multiple disease genes have been identiﬁed. Ar-
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Figure 5 Probability of detecting at least one disease gene when a ﬁxed number of top-ranked positional candidate genes—as ranked by
Prioritizer—are followed up for each locus. Each locus contains either 100 or 150 genes, and the GOMAPPITP network was employed.
The baselines (dashed lines) show the probability of detecting at least one disease gene if a ﬁxed number of arbitrarily chosen genes in each
locus are followed up.
tiﬁcial susceptibility loci, each comprising 100 genes,
were constructed around 10 putative breast cancer genes
described in OMIM (as of March 1, 2005). For each of
the four networks, we then determined how many of
the disease genes were ranked within the top 10 per
locus. The MAPPI network ranked two disease genes
(PIK3CA and CHEK2) in the top 10, whereas the GO
network ranked three (BRCA2, NCOA3, and CHEK2),
and the GOMAPPI network ranked four (BARD1,
PIK3CA, TP53, and CHEK) (ﬁg. 6). However, the
GOMAPPITP network, which integrates the most
information, performed the worst; of the 10 disease
genes now known, only 2 (BARD1 and BRCA1) were
ranked in the top 10. This can be explained by the ob-
servation that the true-positive set contained many
known interactions for these 10 breast cancer genes. As
the ranking procedure corrects for the topology of the
network, these disease genes, with a marked increase
in the number of relationships with other genes in this
most comprehensive network, were suddenly no longer
ranked as high. This became evident when the genes
were ranked using the GOMAPPITP network but
the differences in topology were not corrected for: 9 of
the 10 breast cancer genes were then in the top 10 per
locus.
Prioritizer Availability
To allow researchers to analyze susceptibility loci of
interest, we developed a Java application that can be
downloaded, along with regularly updated gene network
deﬁnition ﬁles and source code from the Prioritizer Web
site. After a set of susceptibility loci has been entered,
Prioritizer ranks the positional candidate genes in each
locus by using the method described above in conjunc-
tion with one of the four gene networks. It can generate
two- and three-dimensional graphs of the top-ranked
positional candidate genes, which allows the user to vi-
sually inspect how the genes within the different loci
interact with each other.
Discussion
In this study, we describe the construction of a functional
human gene network of considerable accuracy (ﬁg. 3;
). As such, it can be used to assess inter-AUCp 90%
actions for a gene of interest through the bioinformatics
tools that we have made available online. We have
shown that, in cases where multiple genes underlie a
disorder, these genes tend to have more functional in-
teractions. When these functional interactions are em-
ployed to prioritize known disease genes in artiﬁcial sus-
ceptibility loci, the chance of detecting disease genes is
increased considerably (2.8 fold).
In breast cancer, 4 of the 10 disease genes were ranked
in the top 10 when the GOMAPPI network was
applied, a fourfold enrichment over the single disease
gene that would be picked up by chance. As has been
discussed earlier, the correction for differences in topol-
ogy is needed to prevent bias toward highly connected
genes. However, this puts diseases in which underlying
genes have a high degree of connectivity at a disadvan-
tage, which was apparent in the analysis of breast cancer
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Figure 6 Prioritizer analysis of breast cancer. Susceptibility loci, each containing 100 genes, were deﬁned around 10 known breast cancer
genes. The 10 highest-ranked genes for each locus are shown in the graph, with colors indicating the locus in which they reside. Use of the
GOMAPPI network led to four breast cancer genes (PIK3CA, CHEK2, BARD1, and TP53 [circles]) being ranked in the top 10. Chr. p
chromosome.
by use of the GOMAPPITP network. When this
topology correction was omitted for breast cancer, the
ranking of the disease genes improved considerably, to
include 9 of the 10 genes. The availability of new high-
throughput data sets will alleviate this problem in the
future, by providing novel interactions for genes that
currently have a low degree of connectivity, which will
reduce the penalty on highly connected genes.
We noticed that the performance of Prioritizer was
lower for complex disorders than for Mendelian dis-
orders. This is likely caused by the fact that the etiology
of complex diseases is more subtle and involves multiple
pathways, so that most of the disease genes only confer
a modest increased risk. Greater coverage of the gene
network, leading to identiﬁcation of relationships be-
tween genes that bridge the various pathways, could
probably help to alleviate this problem.
When the accuracy of the various gene networks was
assessed by investigation of their respective ROCs, it was
envisaged that the GOMAPPI network would per-
form at least at a similar level in prioritizing disease genes
as the GO network, because its AUC was greater. How-
ever, contrary to our expectation, when the positional
candidate genes were prioritized, the disease genes in some
diseases were ranked lower with the GOMAPPI
network than with the GO network. One explanation
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could be that, within the microarray coexpression data
sets (the main contributor to the MAPPI network), we
did not distinguish between coexpression and coregu-
lation. As such, many direct interactions between genes
were inferred, but a large proportion of these interac-
tions were actually indirect. Methods have recently
appeared33,49 that could help remove some of these in-
correctly inferred interactions.
In a somewhat comparable method by Turner et al.,21
positional candidate genes are prioritized by determining
which genes share InterPro50 domains and GO terms, as
a measure to relate genes in susceptibility loci with each
other. Our method extends this approach by also allow-
ing for indirect relationships between individual disease
genes, since Prioritizer uses the graph-theoretic distance
between genes to relate them. Both approaches still rely
largely on manual annotation, which is detrimental for
genes that have not been investigated extensively. When
no experimental evidence for interaction is available,
there is only a small chance that these potential disease
genes, residing in one speciﬁc susceptibility locus, will
be associated with disease genes in other loci, since the
sharing of GO or InterPro terms between these genes
will be minimal. Although GO contributes the most to
the performance of the Bayesian classiﬁer, we should not
depend entirely on a prediction if there is substantial
evidence only from GO, while the evidence from the
other data sets is lacking, for a speciﬁc gene pair, because
the GO evidence has been inferred from the sharing of
predominantly manually annotated terms, whereas the
other sources rely more on direct biological measure-
ments. It is expected that, when additional high-through-
put data sets become available and their coverage of all
possible functional interactions increases, GO evidence
will be supplemented by experimental data, resulting in
better predictions.
As such, an extensive and reliable functional gene net-
work is crucial for good performance of our method. If
this network is inaccurate or biased toward known
genes, the ranking of true disease genes in the suscep-
tibility loci will deteriorate. Several rapidly expanding
data repositories are now becoming available that
should help to improve our network. They include text
mining methods,51,52 which extract functional relation-
ships from the literature, and methods that integrate re-
sults from high-throughput proteomic approaches.53
Our gene network, which, in its current form, has been
applied to genetic linkage analysis, can also be used for
other applications. Recently, efforts have been made to
prioritize positional candidate genes on the basis of their
expression,54 with the assumption that differences in ex-
pression behavior in comparisons of patients with con-
trols may be due to cis-acting variants in the underlying
genes. However, it has turned out that, in most genes,
differences in expression are determined by genetic var-
iation in genes located elsewhere.55,56 The reconstructed
functional gene network can help to relate the observed
differences in gene expression to the underlying causative
genetic variants in other genes, which might help in iden-
tifying the disease genes.
Prioritizer might also be well suited for genomewide
SNP association studies. Technical improvements in con-
junction with decreasing costs now allow researchers to
perform these studies in complex diseases, thereby con-
siderably increasing the resolution at which one can as-
sess genetic variation. However, as the number of tested
SNPs increases, the number of tested individuals re-
quired to achieve sufﬁcient power will also rise. To help
overcome this problem, a new statistical method has
recently been developed57 that combines evidence from
the most-signiﬁcant tests, under the assumption that
there are multiple true associations in the disease under
investigation. However, within this conﬁned set, the ma-
jority of genes will still be false positives because of
power issues. Our positional candidate-gene prioritiza-
tion method can easily be adapted to help distinguish
true disease-associated genes and false-positive genes, by
assuming that the true disease genes are mostly func-
tionally related and will therefore be closer to each other
in the gene network than to the false-positive genes that
have been randomly selected.
We have demonstrated that it is feasible to use gene
networks to prioritize positional candidate genes in var-
ious heritable disorders with multiple associated genes,
even when the susceptibility loci are fairly large. As such,
this article and the proposed methods show that the
integration of gene networks with various genetic studies
can be useful in identifying disease genes. We envisage
that improvements both in the quality of the data sets
making up these gene networks and in the statistical
methods incorporating the networks will result in new,
genetically testable hypotheses.
Acknowledgments
We thank Jackie Senior and members of the Complex Ge-
netics Section and the Department of Human Genetics for crit-
ically reading the manuscript. This study was supported by
Netherlands Organization for Scientiﬁc Research grant 901-
04-219 and by a grant from the Celiac Disease Consortium,
an innovative cluster approved by the Netherlands Genomics
Initiative and partially funded by a Dutch government grant
(BSIK03009).
Web Resources
The URLs for data presented herein are as follows:
Biomolecular Interaction Network Database (BIND), http://bind.ca/
Ensembl, http://www.ensembl.org/index.html
GeneNetwork, http://www.genenetwork.nl
Human Protein Reference Database (HPRD), http://www.hprd.org/
1024 The American Journal of Human Genetics Volume 78 June 2006 www.ajhg.org
Kyoto Encyclopedia of Genes and Genomes (KEGG), http://www
.genome.jp/kegg/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/Omim/
Prioritizer, http://www.prioritizer.nl
Reactome, http://www.reactome.org/
References
1. Jacobi FK, Broghammer M, Pesch K, Zrenner E, BergerW,Meindl
A, Pusch CM (2000) Physical mapping and exclusion of GPR34
as the causative gene for congenital stationary night blindness type
1. Hum Genet 107:89–91
2. Seri M, Martucciello G, Paleari L, Bolino A, Priolo M, Salemi G,
Forabosco P, Caroli F, Cusano R, Tocco T, Lerone M, Cama A,
Torre M, Guys JM, Romeo G, Jasonni V (1999) Exclusion of the
Sonic Hedgehog gene as responsible for Currarino syndrome and
anorectal malformations with sacral hypodevelopment. Hum Ge-
net 104:108–110
3. Simard J, Feunteun J, Lenoir G, Tonin P, Normand T, Luu The
V, Vivier A, et al (1993) Genetic mapping of the breast-ovarian
cancer syndrome to a small interval on chromosome 17q12-21:
exclusion of candidate genes EDH17B2 and RARA. Hum Mol
Genet 2:1193–1199
4. Tumer Z, Croucher PJ, Jensen LR, Hampe J, Hansen C, Kal-
scheuer V, Ropers HH, Tommerup N, Schreiber S (2002)Genomic
structure, chromosome mapping and expression analysis of the
human AVIL gene, and its exclusion as a candidate for locus for
inﬂammatory bowel disease at 12q13-14 (IBD2). Gene 288:179–
185
5. Walpole SM, Ronce N, Grayson C, Dessay B, Yates JR, Trump
D, Toutain A (1999) Exclusion of RAI2 as the causative gene for
Nance-Horan syndrome. Hum Genet 104:410–411
6. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K,
Tavtigian S, Liu Q, et al (1994) A strong candidate for the breast
and ovarian cancer susceptibility gene BRCA1. Science 266:66–
71
7. Joenje H, Patel KJ (2001) The emerging genetic and molecular
basis of Fanconi anaemia. Nat Rev Genet 2:446–457
8. D’Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA
pathway. Nat Rev Cancer 3:23–34
9. de Winter JP, van der Weel L, de Groot J, Stone S, Waisﬁsz Q,
Arwert F, Scheper RJ, Kruyt FA, Hoatlin ME, Joenje H (2000)
The Fanconi anemia protein FANCF forms a nuclear complex
with FANCA, FANCC and FANCG. Hum Mol Genet 9:2665–
2674
10. Yamashita T, Kupfer GM, Naf D, Suliman A, Joenje H, Asano S,
D’Andrea AD (1998) The Fanconi anemia pathway requires FAA
phosphorylation and FAA/FAC nuclear accumulation. Proc Natl
Acad Sci USA 95:13085–13090
11. Zatz M, de Paula F, Starling A, Vainzof M (2003) The 10 auto-
somal recessive limb-girdle muscular dystrophies. Neuromuscul
Disord 13:532–544
12. Alfarano C, Andrade CE, Anthony K, Bahroos N, Bajec M, Ban-
toft K, Betel D, et al (2005) The Biomolecular InteractionNetwork
Database and related tools 2005 update. Nucleic Acids Res Da-
tabase Issue 33:D418–D424
13. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath
V, Muthusamy B, Gandhi TK, et al (2004) Human Protein Ref-
erence Database as a discovery resource for proteomics. Nucleic
Acids Res Database Issue 32:D497–D501
14. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M (2004)
The KEGG resource for deciphering the genome. Nucleic Acids
Res Database Issue 32:D277–D280
15. Joshi-Tope G, Gillespie M, Vastrik I, D’Eustachio P, Schmidt E,
de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L, Lewis
S, Birney E, Stein L (2005) Reactome: a knowledgebase of bio-
logical pathways. Nucleic Acids Res Database Issue 33:D428–
D432
16. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger
R, Eilbeck K, et al (2004) The Gene Ontology (GO) database and
informatics resource. Nucleic Acids Res Database Issue 32:D258–
D261
17. Ball CA, Awad IA, Demeter J, Gollub J, Hebert JM, Hernandez-
Boussard T, Jin H, Matese JC, Nitzberg M, Wymore F, Zachariah
ZK, Brown PO, Sherlock G (2005) The Stanford Microarray Da-
tabase accommodates additional microarray platforms and data
formats. Nucleic Acids Res Database Issue 33:D580–D582
18. Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux
P, Rudnev D, Lash AE, Fujibuchi W, Edgar R (2005) NCBI GEO:
mining millions of expression proﬁles—database and tools. Nu-
cleic Acids Res Database Issue 33:D562–D566
19. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler
H, Stroedicke M, Zenkner M, Schoenherr A, Koeppen S, Timm
J, Mintzlaff S, Abraham C, Bock N, Kietzmann S, Goedde A,
Toksoz E, Droege A, Krobitsch S, Korn B, Birchmeier W, Lehrach
H, Wanker EE (2005) A human protein-protein interaction net-
work: a resource for annotating the proteome. Cell 122:957–968
20. Lehner B, Fraser AG (2004) A ﬁrst-draft human protein-inter-
action map. Genome Biol 5:R63
21. Turner FS, Clutterbuck DR, Semple CA (2003) POCUS: mining
genomic sequence annotation to predict disease genes. Genome
Biol 4:R75
22. Brunner HG, van Driel MA (2004) From syndrome families to
functional genomics. Nat Rev Genet 5:545–551
23. Birney E, Andrews TD, Bevan P, Caccamo M, Chen Y, Clarke L,
Coates G, et al (2004) An overview of Ensembl. Genome Res 14:
925–928
24. Beaumont MA, Rannala B (2004) The Bayesian revolution in ge-
netics. Nat Rev Genet 5:251–261
25. Egmont-Petersen M, Feelders A, Baesens B (2005) Conﬁdence in-
tervals for probabilistic network classiﬁers. Comput Stat Data
Anal 49:998–1019
26. Jansen R, Yu H, Greenbaum D, Kluger Y, Krogan NJ, Chung S,
Emili A, Snyder M, Greenblatt JF, Gerstein M (2003) A Bayesian
networks approach for predicting protein-protein interactions
from genomic data. Science 302:449–453
27. Lee I, Date SV, Adai AT, Marcotte EM (2004) A probabilistic
functional network of yeast genes. Science 306:1555–1558
28. Xia Y, Yu H, Jansen R, Seringhaus M, Baxter S, Greenbaum D,
Zhao H, Gerstein M (2004) Analyzing cellular biochemistry in
terms of molecular networks. Annu Rev Biochem 73:1051–1087
29. Friedman N, Geiger D, Goldszmidt M (1997) Bayesian network
classiﬁers. Mach Learn 29:131–163
30. Jansen R, Gerstein M (2004) Analyzing protein function on a
genomic scale: the importance of gold-standard positives and neg-
atives for network prediction. Curr Opin Microbiol 7:535–545
31. Lee HK, Hsu AK, Sajdak J, Qin J, Pavlidis P (2004) Coexpression
analysis of human genes across many microarray data sets. Ge-
nome Res 14:1085–1094
32. Ning Z, Cox AJ, Mullikin JC (2001) SSAHA: a fast search method
for large DNA databases. Genome Res 11:1725–1729
33. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R,
Califano A (2005) Reverse engineering of regulatory networks in
human B cells. Nat Genet 37:382–390
34. Shannon CE (1948) A mathematical theory of communication.
Bell Syst Tech J 27:379–423, 623–356
35. Floyd RW (1962) Algorithm 97: shortest path. Commun ACM 5:
345
36. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA
(2005) Online Mendelian Inheritance in Man (OMIM), a know-
www.ajhg.org The American Journal of Human Genetics Volume 78 June 2006 1025
ledgebase of human genes and genetic disorders. Nucleic Acids
Res Database Issue 33:D514–D517
37. Jain A, Zongker D (1997) Feature selection: evaluation, appli-
cation and small sample performance. IEEE Trans Pattern Anal
19:153–158
38. Waller WG, Jain AK (1978) Monotonicity of performance of
Bayesian classiﬁers. IEEE Trans Inform Theory 24:392–394
39. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang
J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR,
Hogenesch JB (2004) A gene atlas of the mouse and human pro-
tein-encoding transcriptomes. Proc Natl Acad Sci USA 101:6062–
6067
40. Stegmaier K, Ross KN, Colavito SA, O’Malley S, Stockwell BR,
Golub TR (2004) Gene expression-based high-throughput screen-
ing (GE-HTS) and application to leukemia differentiation. Nat
Genet 36:257–263
41. Rieger KE, Hong WJ, Tusher VG, Tang J, Tibshirani R, Chu G
(2004) Toxicity from radiation therapy associated with abnormal
transcriptional responses to DNA damage. Proc Natl Acad Sci
USA 101:6635–6640
42. Rieger KE, Chu G (2004) Portrait of transcriptional responses to
ultraviolet and ionizing radiation in human cells. Nucleic Acids
Res 32:4786–4803
43. Barabasi AL, Oltvai ZN (2004) Network biology: understanding
the cell’s functional organization. Nat Rev Genet 5:101–113
44. Ho Y, Gruhler A, Heilbut A, Bader GD, Moore L, Adams SL,
Millar A, et al (2002) Systematic identiﬁcation of protein com-
plexes in Saccharomyces cerevisiae by mass spectrometry. Nature
415:180–183
45. Giot L, Bader JS, Brouwer C, Chaudhuri A, Kuang B, Li Y, Hao
YL, et al (2003) A protein interaction map of Drosophila melano-
gaster. Science 302:1727–1736
46. Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, Bauer
A, Schultz J, et al (2002) Functional organization of the yeast
proteome by systematic analysis of protein complexes. Nature
415:141–147
47. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A,
Li N, Berriz GF, et al (2005) Towards a proteome-scale map of
the human protein-protein interaction network. Nature 437:
1173–1178
48. Vidalain PO, Boxem M, Ge H, Li S, Vidal M (2004) Increasing
speciﬁcity in high-throughput yeast two-hybrid experiments.
Methods 32:363–370
49. Egmont-Petersen M, de Jonge W, Siebes A (2004) Discovery of
regulatory connections in microarray data. In: Proceedings of the
8th European Conference on Principles and Practice of Knowledge
Discovery in Databases, pp 149–160
50. Mulder NJ, Apweiler R, Attwood TK, Bairoch A, Bateman A,
Binns D, Bradley P, et al (2005) InterPro, progress and status in
2005. Nucleic Acids Res Database Issue 33:D201–D205
51. Yandell MD,MajorosWH (2002) Genomics and natural language
processing. Nat Rev Genet 3:601–610
52. Malik R, Siebes A (2005) CONAN: an integrative system for
biomedical literature mining. Lect Notes Artif Intell 3808:248–
259
53. Bader JS, Chaudhuri A, Rothberg JM, Chant J (2004) Gaining
conﬁdence in high-throughput protein interaction networks. Nat
Biotechnol 22:78–85
54. Franke L, van Bakel H, Diosdado B, van Belzen M, Wapenaar M,
Wijmenga C (2004) TEAM: a tool for the integration of expres-
sion, and linkage and association maps. Eur J Hum Genet 12:
633–638
55. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spiel-
man RS, Cheung VG (2004) Genetic analysis of genome-wide
variation in human gene expression. Nature 430:743–747
56. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, Colinayo V,
Ruff TG, Milligan SB, Lamb JR, Cavet G, Linsley PS, Mao M,
Stoughton RB, Friend SH (2003) Genetics of gene expression sur-
veyed in maize, mouse and man. Nature 422:297–302
57. Dudbridge F, Koeleman BP (2004) Efﬁcient computation of sig-
niﬁcance levels for multiple associations in large studies of cor-
related data, including genomewide association studies. Am JHum
Genet 75:424–435
